Prospective Clinical Evaluation of the Safety and Performance of the Aesthetic Medical Device MEC REGENERATE® (Injectable Recombinant Collagen-based Product)

NCT07413445 | Not Yet Recruiting

• 1 other identifier: NS/MD04/2025/MecReg
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Prospective, spontaneous, open-label pre-market clinical trial with a single injection session; monitoring visits at baseline and 60 days post-treatment. Two visits will be conducted during the study:

• a baseline visit, during which the first injection will be administered
• a final visit, 60 days after the baseline visit, for final assessment The experimental design involves injection into the deep subdermal layer with the investigational product during the baseline visit, following the study procedure assessments. Typically, 0.9 ml per side of the face is administered using the retrograde fan technique. The study duration is 2 months; safety evaluation will be conducted using non-invasive instrumental assessments such as skin hydration (corneometry) and medical device safety and subjective assessments (see below).

Conditions

Laxity; Skin; Volume Deficiency in the Mid-Face; Wrinkles

Outcome Measures

Primary Outcomes (1)

• Safety based on number of adverse events from the enrollment for the 60days till the second visit and study closing.

  The AE will be monitored in terms on number by severity compared to standard

  From enrollment to the end of treatment, at 60 days

Secondary Outcomes (1)

• Efficacy based on skin hydration measured with corneometer and assessment with WSRS

  At the end of treatment, after 60 days

Study Arms (1)

Injectable device with recombenant collagen, PCL and amino acids

EXPERIMENTAL

Device: Treatment with experimental device

Interventions

Treatment with experimental device DEVICE

Injection of recombinant collagen-based product

Injectable device with recombenant collagen, PCL and amino acids

Eligibility Criteria

• Age: 35 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Both sexes;
• Caucasian race;
• Aged between 35 and 65 years;
• Non-smokers;
• Willing and able to return to the study site for post-procedural assessments;
• Agree to attend all study visits without makeup;
• Agree not to change their habits regarding diet, physical activity, facial makeup, cosmetics, and facial cleansing products;
• Agree to avoid intense UV exposure (UV sessions or sunbathing) during the entire study period without adequate sun protection;
• Agree to take precautions to prevent pregnancy (applicable only to non-menopausal female subjects), including abstinence, intrauterine device (IUD), progestin implants, combined estrogen-progestin contraceptives, or condom use;
• Agree to sign the informed consent form.

You may not qualify if:

• Pregnancy (applicable only to non-menopausal female subjects);
• Breastfeeding (applicable only to non-menopausal female subjects);
• Smokers;
• Alcohol abuse and/or drug use;
• Non-menopausal female subjects not using the specified contraceptive measures to prevent pregnancy during the study;
• Body mass index (BMI) variation of ±1 during the study period;
• History of aesthetic skin treatments (biomaterial implants, facelift, botulinum toxin injections, laser therapy, chemical peels) within 6 months prior to the study start;
• Previous permanent filler treatments;
• Changes in normal habits related to diet, physical activity, facial cosmetics, facial cleansing, and makeup within one month prior to the study;
• Sensitivity or allergy to the investigational product or its components (to be assessed by the investigator at baseline);
• Predicted poor compliance with study protocol;
• Participation in a similar study currently or within the past 9 months;
• Dermatological clinical conditions that could interfere with aesthetic outcomes;
• Chronic neurological, immunological, metabolic, cardiovascular, pulmonary, renal, or oncological diseases;
• Current pharmacological treatment with: Anticoagulants, antiplatelet agents, antihistamines, topical or systemic corticosteroids, narcotics, antidepressants, immunosuppressants (except contraceptive or hormonal treatment started more than 1 year prior); Medications that may affect test results as deemed by the investigator.

Sponsors & Collaborators

• 303 Pharma s.r.l.: lead
• Nextrasearch S.r.l.s.: collaborator

Study Sites (1)

Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere Scientifico

Genova, Italy

Location

MeSH Terms

Conditions

Cutis Laxa

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases

Central Study Contacts

Edoardo Raposio, PhD

CONTACT

+39 0105558825; edoardo.raposio@hsanmartino.it

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 27, 2026
• First Posted: February 17, 2026
• Study Start: March 1, 2026
• Primary Completion: April 1, 2026
• Study Completion: May 1, 2026
• Last Updated: February 17, 2026

Record last verified: 2026-02

Locations

IT (1)